β-thalassemia: New therapeutic Modalities, Genetics, Complications, Quality of life
1Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
3Fondazione IRCCS “Ca' Granda” Policlinico Ospedale Maggiore, University of Milan, Italy
β-thalassemia: New therapeutic Modalities, Genetics, Complications, Quality of life
Description
ß-Thalassemia, the most common genetic blood disorder, results from a decrease in the ß-globin chain synthesis which leads to hemolysis and ineffective erythropoiesis. These patients face considerable mortality and morbidity due to multiple organ involvement. However, considerable development in scientific facilities and comprehensive supportive care have helped decrease mortality and improve the quality of life in thalassemic patients. Genotypic variability causes different phenotypes with poor correlation between genotypes and phenotypes. The nature of these genetic modifiers is still unclear and deserves particular attention from researchers. Many efforts have been focused on the development of new oral iron chelating agents as well as noninvasive accurate techniques for the measurement of iron deposits for evaluating the efficacy of chelation therapy.
We invite researchers to submit original or review articles discussing the most recent therapeutic modalities, genetics, latest iron chelation approaches, supportive care, and management of complications. We are also interested in the manuscripts with the subject of experimental therapy with cellular molecular modifiers promoting the synthesis of fetal hemoglobin (HbF), as well as molecular modifiers through gene therapy. Potential topics include, but are not limited to:
- Experimental studies using new therapeutic agents which augment fetal hemoglobin production
- Experimental molecular therapy (gene therapy)
- Hematopoietic stem cell transplantation
- Iron overload: assessment of the new accurate diagnostic methods as well as evaluation of the efficacy and safety of new oral chelating agents
- Challenges in developing countries
- Management of the disease-related complications
- Genetic study
- Transfusion-related problems
- Latest progress in prenatal diagnosis
- Pregnancy
- Thalassemia intermedia
- Transition of the thalassemic patient from childhood to adult care
- Growth retardation in pediatric thalassemic patients
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ane/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: